湖北亨迪药业股份有限公司 章程 二〇二五年九月 | 第一节 | 股份发行 3 | | --- | --- | | | 第二节 股份增减和回购 4 | | | 第三节 股份转让 5 | | | 第一节 股东的一般规定 6 | | | 第二节 控股股东和实际控制人 9 | | | 第三节 股东会的一般规定 11 | | | 第四节 股东会的召集 13 | | | 第五节 股东会的提案与通知 15 | | | 第六节 股东会的召开 17 | | | 第七节 股东会的表决和决议 20 | | | 第一节 董事的一般规定 25 | | | 第二节 董事会 29 | | | 第三节 独立董事 33 | | | 第四节 董事会专门委员会 37 | | 第七章 | 财务会计制度、利润分配和审计 41 | | 第一节 | 财务会计制度 | 41 | | --- | --- | --- | | 第二节 | 内部审计 | 44 | | 第三节 | 会计师事务所的聘任 | 45 | | 第一节 | 通知 45 | | | 第二节 | 公告 | 46 | | 第一节 | 合并、分立、增资和减资 | 46 | | 第二节 | 解散和清算 ...

Group 1 - The core point of the article is that Hendi Pharmaceutical (301211) reported a total of 18,041 shareholders as of August 20, 2025 [1]

Core Viewpoint - The company has announced its 2025 semi-annual profit distribution plan, which includes a capital reserve increase of 4.5 shares for every 10 shares held, resulting in an increase in total share capital from 288 million to 417.6 million shares [1][2]. Group 1: Profit Distribution Plan - The profit distribution plan was approved at the shareholder meeting held on August 18, 2025, allowing for a capital reserve increase of 4.5 shares for every 10 shares held [1][2]. - The total share capital will increase from 288 million shares to 417.6 million shares following the distribution [2]. Group 2: Shareholder Information - The distribution will be applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the close of trading on August 26, 2025 [2]. - The shares will be credited to shareholders' accounts on August 27, 2025, with fractional shares being allocated based on a specific sorting method [2]. Group 3: Share Capital Changes - The company will adjust the total share capital based on the number of shares on the record date if there are changes due to convertible bonds, share buybacks, or other reasons [1][2]. - The adjusted minimum selling price for shares after the distribution will be set at 13.92 yuan per share [4].

Group 1 - The core point of the article is that Hendi Pharmaceutical plans to increase its share capital by issuing 4.5 additional shares for every 10 shares held by shareholders, without arranging for cash dividends [1] - As of August 19, 2025, Hendi Pharmaceutical's stock price is 18.80 yuan, reflecting a 0.43% increase from the previous trading day, with a trading volume of 113 million yuan [1] - For the first half of 2025, the company reported revenue of 235 million yuan and a net profit attributable to shareholders of 18.55 million yuan [1] Group 2 - Hendi Pharmaceutical operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of APIs and formulations, with products in the fields of antipyretic analgesics and anti-infectives [1] - On the same day, the net inflow of main funds was 9.0143 million yuan, accounting for 0.17% of the circulating market value, while the net outflow over the past five days was 15.5961 million yuan, representing 0.29% of the circulating market value [1]

证券代码：301211 证券简称：亨迪药业 公告编号：2025-036 湖北亨迪药业股份有限公司 关于 2025 年半年度利润分配实施公告 本公司及董事会全体成员保证公告内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）2025 年半年度权益分派 方案已获 2025 年 8 月 18 日召开的 2025 年第一次临时股东大会审议通过，现将 权益分派事宜公告如下： 一、股东大会审议通过利润分配方案的情况 1、湖北亨迪药业股份有限公司于 2025 年 8 月 18 日召开 2025 年第一次临时 股东大会，审议通过《2025 年半年度利润分配预案》，同意公司以总股本 288,000,000 股为基数向全体股东每 10 股派发现金股利人民币 0 元（含税）， 送红股 0 股（含税），以资本公积金向全体股东每 10 股转增 4.5 股。剩余未分 配利润结转下一年度。 如在本公告披露之日起至实施权益分派股权登记日期间，由于可转债转股、 股份回购、股权激励行权及再融资新增股份上市等原因导致公司总股本发生变动 的，则以实施分配方案时股权登记日的总股本为基数，公 ...

Group 1 - The company announced the holding of its first extraordinary general meeting of shareholders in 2025 on August 18, 2025 [2] - The meeting will review and approve the "2025 Half-Year Profit Distribution Plan" [2]

证券代码：301211 证券简称：亨迪药业 公告编号：2025-035 湖北亨迪药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情况； 2、本次股东大会不涉及变更以往股东大会已通过决议的情况； 3、本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席的情况 （一） 会议召开情况 1、会议召开时间： 本次股东大会的召集、召开符合有关法律、行政法规、部门规章、 规范性文件和公司章程等的规定。 （二）会议出席情况 1、出席会议的总体情况 本次会议现场出席及网络出席的股东和股东代表共 143 人，代表 股份 193,095,220 股，占公司有表决权股份总数的 67.0470％。 2、现场会议出席情况 （1）现场会议召开时间：2025 年 8 月 18 日（星期一）下午 14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投 票的具体时间为：2025 年 8 月 18 日上午 9:15-9:25，9:30-11:30， 下午 13:00 ...

上海市锦天城（武汉）律师事务所 关于湖北亨迪药业股份有限公司 二○二五年第一次临时股东大会的 地址：武汉市江汉区云霞路 187 号民生金融中心 8 层 03-05 电话：027-83828888 邮编：430030 上海市锦天城（武汉）律师事务所 法律意见书 上海市锦天城（武汉）律师事务所 关于湖北亨迪药业股份有限公司 法律意见书 法律意见书 二○二五年第一次临时股东大会的 致：湖北亨迪药业股份有限公司 上海市锦天城（武汉）律师事务所（以下简称"本所"）接受湖北亨迪药业 股份有限公司（以下简称"公司"）委托，委派本律师通过远程视频方式出席公 司二○二五年第一次临时股东大会（以下简称"本次股东大会"）。本律师根据《中 华人民共和国公司法》（以下简称《公司法》）等法律、法规、规章和其他规范性 文件以及《湖北亨迪药业股份有限公司章程》（以下简称《公司章程》）的有关规 定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核 ...

Core Viewpoint - Hubei Hendi Pharmaceutical Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, primarily due to decreased sales of its main product, ibuprofen [1][3]. Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 235 million yuan, a year-on-year decrease of 2.93% [1]. - The net profit attributable to shareholders was 18.55 million yuan, down 72.92% year-on-year [1]. - For the full year of 2024, revenue was 446 million yuan, a decline of 32.75%, and net profit was 91.55 million yuan, down 48.02% [3]. Group 2: Product and Market Challenges - The decline in revenue is attributed to reduced sales of ibuprofen, intensified international market competition, and low pricing [3][4]. - Ibuprofen has historically contributed approximately 80% of the company's total revenue, making it critical to the company's performance [4]. Group 3: Research and Development - The company's R&D expenses have been decreasing, with 32.94 million yuan in 2024 and 15.88 million yuan in the first half of 2025, representing declines of 37.59% and 17.72% respectively [4]. - The reduction in R&D investment may impact future product innovation and market competitiveness [4]. Group 4: Strategic Adjustments - In response to performance pressures, the company is adjusting its fundraising projects, reducing the planned production capacity of raw materials from 1200 tons to 700 tons [5][6]. - The company plans to invest 332 million yuan in a high-end pharmaceutical formulation internationalization project, using both raised and self-owned funds [6]. - The decision to terminate the 5000-ton ibuprofen raw material project was based on market saturation and low pricing in the global market [6][7].

证券日报网讯亨迪药业（301211）8月4日在互动平台回答投资者提问时表示，截至2025年7月31日，公 司股东户数为18153户。 ...